Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.
Market Analysis and Insights: Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market
The global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Surge in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market.Moreover, lifestyle up-gradation, increasing number of smokers are some secondary considerations accountable for rise in global chemotherapy induced acral erythema treatment market.
Report Includes
This report presents an overview of global market for Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Taro, Oceanside Pharmaceuticals, Pfizer, Novartis, A-S Medication Solutions, Preferred Pharmaceuticals, Syntex Pharmaceuticals, Valeant Canada and Technilab Pharma, etc.
By Company
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan
Segment by Type
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others
Segment by Application
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Analgesics
1.2.3 Anti-Inflammatory And Anti-Edematous Agents
1.2.4 Antihistaminic
1.2.5 NSAIDs
1.2.6 Oral/Topical Glucocorticoids
1.2.7 Pyridoxine (Vitamin B6)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pharmacy And Drugstores
1.3.3 Hospital Pharmacy
1.3.4 Online Drug Stores
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Perspective (2018-2029)
2.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Growth Trends by Region
2.2.1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Size by Region (2018-2023)
2.2.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Region (2024-2029)
2.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Dynamics
2.3.1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Industry Trends
2.3.2 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Drivers
2.3.3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Challenges
2.3.4 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment by Players
3.1.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Players (2018-2023)
3.1.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Concentration Ratio
3.4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in 2022
3.5 Global Key Players of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Head office and Area Served
3.6 Global Key Players of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment, Product and Application
3.7 Global Key Players of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Breakdown Data by Type
4.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Size by Type (2018-2023)
4.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Type (2024-2029)
5 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Breakdown Data by Application
5.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Historic Market Size by Application (2018-2023)
5.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2018-2029)
6.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
6.2.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2018-2023)
6.2.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2024-2029)
6.2.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2018-2029)
6.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
6.3.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2018-2023)
6.3.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2024-2029)
6.3.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2018-2029)
6.4 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
6.4.1 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2018-2023)
6.4.3 North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2018-2029)
7.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
7.2.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2018-2023)
7.2.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2024-2029)
7.2.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2018-2029)
7.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
7.3.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2018-2023)
7.3.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2024-2029)
7.3.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2018-2029)
7.4 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
7.4.1 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2018-2023)
7.4.3 Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2018-2029)
8.2 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
8.2.1 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2018-2023)
8.2.2 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2024-2029)
8.2.3 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2018-2029)
8.3 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
8.3.1 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2018-2023)
8.3.2 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2024-2029)
8.3.3 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2018-2029)
9.2 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
9.2.1 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2018-2023)
9.2.2 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2024-2029)
9.2.3 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2018-2029)
9.3 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
9.3.1 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2018-2023)
9.3.2 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2024-2029)
9.3.3 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2018-2029)
9.4 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region
9.4.1 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region (2018-2023)
9.4.3 Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Taro
11.1.1 Taro Company Details
11.1.2 Taro Business Overview
11.1.3 Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.1.4 Taro Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.1.5 Taro Recent Developments
11.2 Oceanside Pharmaceuticals
11.2.1 Oceanside Pharmaceuticals Company Details
11.2.2 Oceanside Pharmaceuticals Business Overview
11.2.3 Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.2.4 Oceanside Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.2.5 Oceanside Pharmaceuticals Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.3.4 Pfizer Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.3.5 Pfizer Recent Developments
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.4.4 Novartis Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.4.5 Novartis Recent Developments
11.5 A-S Medication Solutions
11.5.1 A-S Medication Solutions Company Details
11.5.2 A-S Medication Solutions Business Overview
11.5.3 A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.5.4 A-S Medication Solutions Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.5.5 A-S Medication Solutions Recent Developments
11.6 Preferred Pharmaceuticals
11.6.1 Preferred Pharmaceuticals Company Details
11.6.2 Preferred Pharmaceuticals Business Overview
11.6.3 Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.6.4 Preferred Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.6.5 Preferred Pharmaceuticals Recent Developments
11.7 Syntex Pharmaceuticals
11.7.1 Syntex Pharmaceuticals Company Details
11.7.2 Syntex Pharmaceuticals Business Overview
11.7.3 Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.7.4 Syntex Pharmaceuticals Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.7.5 Syntex Pharmaceuticals Recent Developments
11.8 Valeant Canada
11.8.1 Valeant Canada Company Details
11.8.2 Valeant Canada Business Overview
11.8.3 Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.8.4 Valeant Canada Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.8.5 Valeant Canada Recent Developments
11.9 Technilab Pharma
11.9.1 Technilab Pharma Company Details
11.9.2 Technilab Pharma Business Overview
11.9.3 Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.9.4 Technilab Pharma Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.9.5 Technilab Pharma Recent Developments
11.10 Allergan
11.10.1 Allergan Company Details
11.10.2 Allergan Business Overview
11.10.3 Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Introduction
11.10.4 Allergan Revenue in Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Business (2018-2023)
11.10.5 Allergan Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan
*If Applicable.